Search for: "David Boundy"
Results 101 - 106
of 106
Sort by Relevance
|
Sort by Date
11 Jul 2007, 11:07 am
You may want to talk with David Boundy (DBoundy@Cantor.com) about fighting the rules and Kevin Noonan (noonan@mbhb.com) about how your company should handle the rule changes. [read post]
10 Jul 2007, 10:02 am
” Those interested in trying further steps to limit these rule changes should send an email to David Boundy of Cantor Fitzgerald at: DBoundy@Cantor.com He is exploring two additional avenues: (a) Congressional oversight. [read post]
10 Jul 2007, 8:54 am
To view the brief conclusions of the regulatory review, click here and here.According to David Boundy, who spearheaded the initial challenge, two avenues are being explored for further challenges. [read post]
6 Jul 2007, 11:29 am
McMillin, Deputy Director at the Office of Management and Budget, David Boundy of Cantor Fitzgerald expressed concerns of industry groups about the budget effects of the USPTO’s proposed rules on continuations and claims. [read post]
27 Jun 2007, 11:48 am
David Boundy of Cantor Fitzgerald and Mike Strickland of GlaxoSmithKline attended a meeting with the Office of Management and Budget (OMB) to discuss the USPTO’s Changes to Practice for Continuing Applications, Requests for Continued Examination Practice, and Applications Containing Patentably Indistinct Claims (Fed. [read post]
24 Jun 2007, 7:43 pm
On June 15, David Boundy from Cantor Fitzgerald and Mike Strickland from GlaxoSmithKline appeared at a White House meeting with the Office of Management and Budget (OMB) to discuss the PTO's rules to limit patent applications (link). [read post]
